MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Merck & Co., Inc. for alleged misrepresentations regarding the demand for its vaccine drug Gardasil in China, impacting investor confidence and inventory levels [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Merck securities between February 3, 2022, and February 3, 2025 [1]. - Allegations include that Merck lacked visibility into the demand for Gardasil in China, leading to inflated inventory levels at its distributor, Zhifei [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by April 14, 2025, with the role involving directing the litigation on behalf of the class [3]. - Shareholders can remain absent class members without taking action, and all representation is on a contingency fee basis, meaning no fees or expenses are required from shareholders [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for sixteen consecutive years [4].